Switch to
Predicate | Object |
---|---|
rdf:type | |
calbc:hasCorrelation | |
skos:definition |
NCI: An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.,PDQ: An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance
|
skos:inScheme | |
skos-xl:prefLabel | |
skos-xl:altLabel |
umls-label:A10918342,
umls-label:A10918343,
umls-label:A10918344,
umls-label:A11913943,
umls-label:A13279651,
umls-label:A18056538,
umls-label:A19034276,
umls-label:A12800526,
umls-label:A10802556,
umls-label:A12791854,
umls-label:A17936642,
umls-label:A18032265,
umls-label:A11560211,
umls-label:A18032266,
umls-label:A9368393,
umls-label:A18056539
|